Keeping Track: Nektar Withdraws Oxycodegol NDA As Novel Submission Pileup Continues

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your US review and approval news for the week in brief: Nektar didn't even wait around for the US Food and Drug Administration to make a final decision on the company's novel opioid oxycodegol, as it withdrew the new drug application almost immediately after an advisory committee voted unanimously against approval.

But as one novel product application left the FDA, many others piled into the agency. GlaxoSmithKline PLC's submitted its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers